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According to the American College of Chest Physi-
cians (ACCP) guidelines [1], low-molecular weight hep-
arin and fondaparinux are preferred treatment modali-
ties for acute pulmonary embolism (PE). In addition, in 
selected patients these guidelines recommend throm-
bolytic therapy: in patients presenting with an acute PE 
associated with hypotension and also patients who reveal 
a high risk of developing hypotension. Of note, patients 
managed with fibrinolytic agents should not have a high 
bleeding risk.
Surgical embolectomy or endovascular removal of 
emboli can be an option in selected patients with sub-
massive acute PE, especially those with emerging hemo-
dynamic or respiratory instability. Also, patients who do 
not improve after thrombolysis should be considered for 
surgical or endovascular embolectomy. Recent advances 
in endovascular techniques, such as aspiration thrombec-
tomy, endovascular thrombus fragmentation devices and 
rheolytic or rotational thrombectomy, suggest that the 
endovascular approach can represent an alternative for 
pharmacological thrombolysis and surgical embolecto-
my. Endovascular treatment can be particularly advan-
tageous when a  surgical procedure is not available or 
thrombolytic management is contraindicated [1-5].
Importantly, endovascular procedures should be 
performed exclusively by doctors experienced with the 
techniques and armamentarium in this unique vascular 
territory.
Interventionalists should be aware of the fact that 
severe complications, comprising severe bleeding, cardi-
ac tamponade, cardiogenic shock and bradyarrhythmias, 
are likely to develop during the procedure, and the med-
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We present a technique of endovascular rheolytic thrombectomy using the AngioJet 
system for the treatment of acute pulmonary embolism. We describe the procedure in 
detail, suggesting the optimal catheter, wires and potential complications during the 
procedure. Recent advances in endovascular techniques, such as aspiration throm-
bectomy, endovascular thrombus fragmentation devices and rheolytic or rotational 
thrombectomy, suggest that the endovascular approach can represent an alternative 
for pharmacological thrombolysis and surgical embolectomy.
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ical team of the centre should be ready to manage these 
events. Dissection or perforation of the branches of the 
pulmonary artery with an endovascular device carries 
a high risk of fatal haemorrhage. Therefore, transcatheter 
embolectomy should be limited to the main pulmonary 
artery and lobar branches, since the risk of perforation 
significantly increases in vessels smaller than 6 mm [6-9].
In this technical note we describe the suggested 
approach to the catheter-based pulmonary thrombecto-
my using the rheolytic thrombectomy system AngioJet 
(Boston Scientific, Natick, MA, USA) [10].
ENDOvAsculAr tEchNiquE
Femoral access is the preferred route for this proce-
dure. The femoral vein should be cannulated with a 5F 
or 6F introducer sheath. Then, over the standard (for 
example InQwire Guide Wire, Merit Medical Systems) 
or hydrophilic (for example: 0.035´ ´ AqWire, Covidien, 
ev3 Endovascular, Inc., Plymouth, MN, USA) guidewire 
a pigtail diagnostic catheter should be positioned in the 
pulmonary trunk. This diagnostic catheter should be 
advanced into each pulmonary artery and pulmonary 
angiography should be performed (Fig. 1). Approximate-
ly 10-30 ml of contrast (the volume used should depend 
on the clinical status of the patient and the pulmonary 
pressure) is injected on each side. Injection of contrast 
should be followed by local administration of 5000 units 
of unfractionated heparin (the dose of heparin should 
be adjusted according to activated partial thromboplas-
tin time and should be reduced if the drug has already 
been administered before the procedure). Once PE is 
Technique of endovascular rheolytic thrombectomy using AngioJet for treatment of acute pulmonary embolism
107Phlebological Review 2015
confirmed and a decision to address it using the rheolytic 
embolectomy is made, the introducer sheath should be 
replaced with a  bigger one, preferentially an 8F sheath. 
The embolus should be reached using a multipurpose 8F 
guiding catheter (the AngioJet system is compatible with 
6F and 8F catheters). We suggest using the SiteSeer Jud-
kins Right catheter (Medtronic, Minneapolis, MN, USA) 
or a long sheath with a special tip, such as the Destination 
Guiding Sheath (Terumo, Tokyo, Japan). Through this 
guiding catheter, over a  guidewire that should be navi-
gated across the embolus (preferentially, a  hydrophilic 
Fig. 1. Initial angiography of the pulmonary arteries in a patient 
with pulmonary embolism (RPA – right pulmonary artery)
Fig. 3. Recanalisation of the middle branch of the right pulmo-
nary artery after use of the AngioJet system
Fig. 2. Introduction of AngioJet system into the middle branch 
of the right pulmonary artery 
Fig. 4. Residual thrombi in the upper branch of the right pul-
monary artery (RPA)
Fig. 5. Introduction of AngioJet system into the upper branch of 
the right pulmonary artery
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one, still advanced carefully), the AngioJet system (Bos-
ton Scientific, Natick, MA, USA) is introduced (Fig. 2). 
Using this endovascular device the emboli should be sub-
sequently aspired from all occluded branches (Figs. 3-6). 
In general, embolectomy should be discontinued as soon 
as the patient’s haemodynamic status stabilizes, even if 
the angiographic result is not perfect. As emphasized in 
the introduction, embolectomy of small branches of the 
pulmonary artery should be avoided, because naviga-
tion through these tiny vessels dramatically increases the 
risk of haemorrhage. If the above-described attempts to 
restore the patency of pulmonary arteries are not effec-
tive, direct local administration of a fibrinolytic agent (on 
condition that there are no contraindications for such 
treatment, especially intraprocedural injury of the artery) 
may be helpful. During aspiration of embolic materi-
al dyspnoea and cardiac decompensation can develop, 
especially if an aspiration lasts longer than 7-10 s. Thus, 
longer use of the AngioJet system should be avoided. 
Also, during the procedure some patients may develop 
bradyarrhythmias. Therefore, some authors recommend 
insertion of a  temporary transvenous pacemaker. Care-
ful preprocedural assessment of the patient should reveal 
whether such a pacemaker is indeed necessary. It should 
also be remembered that hemodynamic instability seen 
in PE patients, especially right ventricle overload, is not 
Fig. 6. Final result of the procedure in this patient (RPA – right 
pulmonary artery)
solely related to mechanical occlusion of pulmonary 
arteries, but also is associated with vasoconstriction of 
the pulmonary vasculature. Although the exact mech-
anism of such vasoconstriction in the setting of PE has 
not yet been elucidated, it is thought that haemolysis 
resulting from PE itself and also from pharmacological 
treatment with fibrinolytic agents reduces the concentra-
tion of nitric oxide (NO) in the pulmonary circulation 
through scavenging of NO by cell-free haemoglobin [11].
Perhaps other vasoactive substances, such as adeno-
sine and bradykinin, may also play a  role in the devel-
opment of pulmonary vasoconstriction. Furthermore, 
severe haemolysis can lead to significant hyperkalaemia 
and also induce renal failure, which should be considered 
when managing PE patients.
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